Edanur Ersöz

Edanur Ersöz

Auto-generated profile, based on publicly available information

Edanur Ersöz

Health Sciences Institute, Department of Gene and Cell Therapy Akdeniz University Antalya Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2024 in Drug Development Research
Verified
Journal Article
Open access
EEEdanur Ersöz
Edanur Ersöz
DDDevrim Demir-Dora
Devrim Demir-Dora
Antisense oligonucleotides (ASOs) are short, synthetic, single‐stranded deoxynucleotide sequences composed of phosphate backbone‐connected sugar rings. Designing of those strands is based on Watson‐Crick hydrogen bonding mechanism. Thanks to rapidly advancing medicine and technology, evolving of the gene therapy area and ASO approaches gain attention. Considering the genetic basis of diseases, it is promising that gene therapy approaches offer more specific and effective options compared to conventional treatments. The objective of this review is to explain the mechanism of ASOs and discuss the characteristics and safety profiles of therapeutic agents in this field. Pharmacovigilance for gene therapy products is complex, requiring accurate assessment of benefit‐risk balance and evaluation of adverse effects.